



Research on Malaria Vaccines

Guest Editor:

Prof. Dr. Jose Manuel Lozano
Department of Pharmacy,
Faculty of Sciences, Universidad
Nacional de Colombia, Bogotá,
Colombia

Deadline for manuscript
submissions:

31 March 2025

Message from the Guest Editor

Dear Colleagues,

This Special Issue will provide updates on the most innovative and promising research into the development of a malaria vaccine.

This Special Issue will discuss innovative works related to malaria vaccine candidates at different levels of development, ranging from designing vaccine candidates and those undergoing pre-clinical testing to others at different clinical trial phases. The development of vaccine candidates for different *Plasmodium* species, such as *P. falciparum* and *P. vivax*, and genetic variants will be considered. Please contribute high-quality reviews, regular research papers, communications, and case reports. Specifically, the Special Issue's research areas may include the following topics:

- Moving beyond frontiers and new challenges related to safe and potent malaria vaccines
- Classical versions of malaria vaccines against pre-erythrocytic stages
- Transmission-blocking vaccines
- Vaccines against *Plasmodium* blood stages
- Development of functional monoclonal antibodies against *Plasmodium* targets
- Rationally designed new generation vaccines
- Natural versus acquired immunity against malaria
- Novel adjuvants for malaria vaccine formulation





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com